Audit in process? Call the number on your audit letter to get options.
Site Logo
Health care professionals website
DPL Global Search
DPL Utility Nav
DPL Main Nav
DPL Global Search
DPL Utility Nav
Breadcrumbs
SubHero Banner
RxNews®
Valuable and timely information on drug therapy issues impacting today's health care and pharmacy environment.
Text
Reyvow™ (lasmiditan) – New drug approval
October 11, 2019 - The FDA announced the approval of Eli Lilly’s Reyvow (lasmiditan), for the acute treatment of migraine with or without aura in adults.